Zhejiang Hisun Pharmaceutical News

Haizheng Pharmaceutical (600267): Improving operating margins and upgrading synthetic biology platforms

Western SecuritiesDec 27, 2024 16:07

Haizheng Pharmaceutical (600267): Continued Improvement of Operating Efficiency+Profitability, Revitalizing New Opportunities for Established Pharmaceutical Companies

Dec 1, 2023 20:52

Haizheng Pharmaceutical (600267) First Coverage Report: Asset Revaluation, Reversal of Difficulties, and Steady Improvement of Profitability

Sep 27, 2023 19:06

Haizheng Pharmaceutical (600267): Asset revaluation, reversal of difficulties, steady improvement in profitability

西部證券Sep 15, 2023 19:22

Deep* Company* Haizheng Pharmaceutical (600267): Performance continues to grow, product pipeline expansion accelerates

中銀證券Aug 23, 2022 00:00

Deep* Company* Haizheng Pharmaceutical (600267): Reached a strategic cooperation agreement with Wangshi Biotech and was entrusted with the production of the COVID-19 oral drug VV116

中銀證券May 20, 2022 19:56

Haizheng Pharmaceutical (600267): The initial implementation of Haizheng Vrui Battle Investment opens up a new situation in the company's development

太平洋證券Sep 4, 2019 00:00

Haizheng Pharmaceutical (600267): Fundamentals are gradually improving, and many major products will soon be approved

西南證券Aug 21, 2019 00:00

Haizheng Pharmaceutical (600267): The inflection point of profit after deduction of profit turned into profit is clear

太平洋證券Aug 20, 2019 00:00

Haizheng Pharmaceutical (600267): Monoclonal monoclonal assets plan to be introduced to further implement investment and industrial integration

太平洋證券Jun 23, 2019 00:00

Haizheng Pharmaceutical Industry (600267): multiple factors drag down performance, R & D and Innovation in 2018 to promote long-term growth

東北證券Apr 25, 2019 00:00

Haizheng Pharmaceutical (600267): The low point has passed and an inflection point is approaching

太平洋證券Apr 24, 2019 00:00

Haizheng Pharmaceutical (600267) Update Report: Biopharmaceuticals+Small Molecule Innovative Drugs Entering Harvest Period

太平洋證券Jan 15, 2019 00:00

Haizheng Pharmaceutical Industry (600267) Quarterly report comments: biological drugs, CSO business good frequent inflection point is coming

太平洋證券Oct 31, 2018 00:00

Haizheng Pharmaceutical Co., Ltd. (600267): Hanhui Pharmaceutical opens the international CSO diabetes line to introduce war investment and accelerate research and development.

浙商證券Oct 16, 2018 00:00

Haizheng Pharmaceutical Industry (600267) comments: the valuation of biological drugs shows that the value of CSO platform begins to reflect.

太平洋證券Oct 16, 2018 00:00

海正药业(600267)点评：阿达木单抗报生产获受理 生物药步入收获期

太平洋證券Sep 17, 2018 00:00

海正药业(600267)季报点评：制剂销售走出低谷 在研产品进展顺利

東吳證券Nov 1, 2016 00:00

【东吴证券】海正药业:制剂销售走出低谷,在研产品进展顺利

東吳證券Oct 31, 2016 00:00

海正药业(600267)年报点评：经营触底 2016年利润有望好转

中金公司Apr 8, 2016 00:00